Michael R. Pavia

Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem.

Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem.

Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem.

Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem.

Azevan Pharmaceuticals, Inc. develops novel therapeutics to treat disorders of stress, mood, and behavior. Its first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and major depression. The company was founded by Craig F. Ferris and Neal Gordon Simon in 1999 and is headquartered in Bethlehem.